Huisman Floor, Cieslak Kasia P, van Lienden Krijn P, Bennink Roelof J, van Gulik Thomas M
Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands.
Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands.
Hepatobiliary Surg Nutr. 2017 Dec;6(6):379-386. doi: 10.21037/hbsn.2017.02.03.
Portal vein embolization (PVE) is used preoperatively in patients to increase future remnant liver volume (FRLV). Unfortunately, some patients are found to be unresectable at exploration due to tumor progression or new lesions. The aim of this study is to evaluate the long-term effects of PVE in the embolized liver lobe when left unresected.
Of 85 patients who underwent right PVE, 16 (19%) were unresectable (PVE-group). These patients were compared with 48 randomly matched patients from a pool of 75 unresectable patients who had not undergone PVE. Primary outcome parameter was occurrence of infectious complications (liver abscesses) on follow-up imaging of the liver. The long-term volumetric changes of the hypertrophy/atrophy complex were assessed as secondary outcome parameter.
Five of 16 (31%) patients in PVE-group developed an abscess 4 (8%) patients in non-PVE group (P=0.022). The volume distribution of left and right liver lobes (hypertrophy-atrophy rate) increased from 26%:74% before embolization to 36%:64% three weeks after PVE and to 51%:49% six months after PVE.
Persistence of embolized liver lobe in unresectable patients after PVE resulted in abscesses in 31%. This observation calls for developing reversible embolization techniques using absorbable materials in patients with uncertain resectability.
门静脉栓塞术(PVE)术前用于患者以增加未来残余肝体积(FRLV)。不幸的是,一些患者在探查时因肿瘤进展或出现新病灶而无法切除。本研究的目的是评估PVE后未切除的栓塞肝叶的长期影响。
在85例行右半肝PVE的患者中,16例(19%)无法切除(PVE组)。将这些患者与75例未行PVE的无法切除患者中随机匹配的48例患者进行比较。主要结局参数是肝脏随访成像时感染并发症(肝脓肿)的发生情况。肥大/萎缩复合体的长期体积变化作为次要结局参数进行评估。
PVE组16例患者中有5例(31%)发生脓肿,非PVE组48例患者中有4例(8%)发生脓肿(P=0.022)。左右肝叶的体积分布(肥大-萎缩率)从栓塞前的26%:74%增加到PVE后3周的36%:64%,以及PVE后6个月的51%:49%。
PVE后无法切除的患者中栓塞肝叶持续存在导致31%的患者发生脓肿。这一观察结果要求针对可切除性不确定的患者开发使用可吸收材料的可逆栓塞技术。